ClinicalTrials.gg
RecruitingNCT07852624ATHNCDUpdated Oct 8, 2026

Comparison of Different Anesthetic Techniques on Hearing Outcomes in Neonates After Cesarean Delivery

An interventional study of Combined spinal-epidural anesthesia and General Anesthesia (GA) in Pregnancy and Neonatal Hearing Function, sponsored by Second Affiliated Hospital of Wenzhou Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Second Affiliated Hospital of Wenzhou Medical University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2025, registered Sep 2026).
  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 8, 2026Newly registered1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

This is a single-center, prospective, single-blind randomized controlled trial. The investigators plan to recruit 144 pregnant women scheduled for cesarean delivery. Participants will be randomly assigned to receive either combined spinal-epidural anesthesia (CSEA) or general anesthesia (GA). The study aims to compare the effects of these two anesthetic techniques on neonatal hearing after cesarean delivery. The investigators will collect neonatal transient evoked otoacoustic emission (TEOAE) screening results and conduct follow-up hearing assessments at 3-6 months of age for infants who fail repeat screening. The investigators will also record maternal intraoperative hemodynamic changes, the interval from anesthesia initiation to neonatal delivery, neonatal Apgar scores at 1 and 5 minutes, and maternal postoperative pain scores at multiple time points.

Read the detailed description

This is a single-center, prospective, single-blind, parallel-group randomized controlled trial. A total of 144 eligible parturients undergoing cesarean section will be enrolled and randomly allocated in a 1:1 ratio to the combined spinal-epidural anesthesia (CSEA) group or general anesthesia (GA) group. An independent statistician will generate the randomization sequence using a computerized random number table. Allocation concealment will be maintained using sealed, opaque, sequentially numbered envelopes, which will be opened by an independent coordinator after enrollment.

Participants will not be informed of their assigned anesthesia group. Anesthesia providers and surgical teams will be aware of group assignment. All outcome assessors, including personnel recording hemodynamic data, assessing Apgar scores, performing TEOAE hearing screening, and collecting postoperative VAS pain scores and adverse-event data, will remain blinded to group allocation to reduce assessment bias.

The investigators will compare maternal intraoperative hemodynamic changes and record the interval from anesthesia administration to neonatal delivery. Neonatal Apgar scores will be recorded at 1 and 5 minutes. Maternal postoperative Visual Analogue Scale (VAS) pain scores will be collected at 1, 6, 12, 24, and 48 hours after surgery. Neonatal hearing outcomes will include initial and repeat transient evoked otoacoustic emission (TEOAE) screening results. Infants who fail repeat screening will undergo further hearing assessment at 3-6 months of age to identify hearing loss.

02

Conditions studied

  • Pregnancy
  • Neonatal Hearing Function

Keywords

  • Cesarean section
  • Combined spinal-epidural anesthesia
  • General anesthesia
  • Neonatal hearing
  • Transient evoked otoacoustic emission
03

In context

Lead sponsor

Second Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 137 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:(a) Singleton pregnancy with gestational age 37-42 weeks; (b) Maternal age 18-35 years; (c) (ASA) physical status II; (d) Scheduled for elective cesarean delivery based on clinical indications; (e) Written obtained from the parturient and her family.

Exclusion Criteria:

  1. Refusal to participate;
  2. to neuraxial anesthesia;
  3. Severe comorbidities, including hypertensive disorders of pregnancy, cardiovascular disease, hepatic or renal dysfunction, or coagulation abnormalities;
  4. History of psychiatric disorders, severe anxiety or depression, or chronic preoperative use of sedative or analgesic medications;
  5. Neonatal hyperbilirubinemia or birth weight \<2,500 g;
  6. Anticipated intraoperative conditions that would prevent completion of the study per the prespecified protocol.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Active comparator
    Combined Spinal-Epidural Anesthesia Group (CSEA Group)

    Participants receive combined spinal-epidural anesthesia for elective cesarean section. Intraoperative hemodynamic parameters, time from anesthesia initiation to fetal delivery, neonatal Apgar scores, postoperative VAS pain scores and neonatal TEOAE hearing screening results will be collected.

    Procedure: Combined spinal-epidural anesthesia

  • Active comparator
    General Anesthesia Group (GA Group)

    Participants receive general anesthesia for elective cesarean section. The same set of maternal and neonatal indicators will be collected and compared with the CSEA group.

    Procedure: General Anesthesia (GA)

Interventions

  • ProcedureCombined spinal-epidural anesthesia

    Combined spinal-epidural anesthesia is administered for elective cesarean section according to the study protocol

  • ProcedureGeneral Anesthesia (GA)

    General anesthesia performed for cesarean delivery

06

What researchers measure

Primary outcomes

  1. 1. Neonatal hearing screening pass rate by transient evoked otoacoustic emission (TEOAE)

    The pass rate of neonatal transient evoked otoacoustic emission (TEOAE) hearing screening within 72 hours after birth.

    Time frame: Within 72 hours after delivery

Secondary outcomes

  1. Maternal intraoperative hemodynamic changes

    Changes in maternal blood pressure and heart rate during cesarean section.

    Time frame: during surgery

  2. Neonatal Apgar scores

    Apgar scores will be assessed at 1 and 5 minutes after birth. The Apgar score evaluates five components: Appearance, Pulse, Grimace, Activity, and Respiration. The total score ranges from 0 to 10, with higher scores indicating better neonatal condition and a better outcome.

    Time frame: 1 minute and 5 minutes after birth

  3. Postoperative maternal VAS pain score

    Postoperative maternal pain intensity will be assessed using the Visual Analog Scale (VAS) at 1, 6, 12, 24, and 48 hours after cesarean delivery. The VAS ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity and therefore a worse outcome.

    Time frame: 1 hour, 6 hours, 12 hours, 24 hours and 48 hours after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data including baseline characteristics, intraoperative variables, postoperative VAS pain scores, and neonatal hearing screening results will be shared.

Supporting information: Study protocol, Analytic code

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Jun 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartActual
Aug 2, 2025
Primary completionActual
Jun 1, 2026
CompletionEst.
Oct 25, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • The Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
Show 1 removed
  • The Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
Oct 8, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionNeonatal Apgar scores: how it is measured was reworded
  • DescriptionPostoperative maternal VAS pain score: how it is measured was reworded
Oct 8, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 8, 2026
    1 site added, 1 site removed
    Show site
    • The Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
    Show 1 removed
    • The Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionNeonatal Apgar scores: how it is measured was reworded
    • DescriptionPostoperative maternal VAS pain score: how it is measured was reworded
    + 2 other changes: description and conditions
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852624
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Aug 2, 2025
Primary completion
Jun 1, 2026
Completion
Oct 25, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Baiping Mao, PhD
Contact
baipingmaowmu@163.com
+860577-85676879

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion